What is Wedbush’s Estimate for TYRA FY2029 Earnings?

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Stock analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Tyra Biosciences in a research note issued to investors on Friday, March 28th. Wedbush analyst R. Driscoll expects that the company will post earnings per share of ($0.91) for the year. Wedbush currently has a “Outperform” rating and a $30.00 target price on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share.

TYRA has been the subject of several other reports. UBS Group initiated coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $30.83.

Tyra Biosciences Trading Up 1.1 %

Shares of TYRA stock opened at $9.77 on Monday. The company has a market cap of $494.39 million, a PE ratio of -6.07 and a beta of 1.09. The company’s fifty day simple moving average is $12.46 and its 200-day simple moving average is $16.30. Tyra Biosciences has a 52 week low of $9.49 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Nina S. Kjellson sold 3,993 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the completion of the sale, the director now owns 3,707,420 shares in the company, valued at $60,653,391.20. This trade represents a 0.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 21,998 shares of company stock worth $344,818 in the last quarter. 15.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently made changes to their positions in the business. KLP Kapitalforvaltning AS bought a new stake in shares of Tyra Biosciences in the fourth quarter worth $31,000. US Bancorp DE acquired a new position in Tyra Biosciences during the 4th quarter worth $50,000. BNP Paribas Financial Markets bought a new stake in shares of Tyra Biosciences in the 4th quarter worth about $60,000. Aquatic Capital Management LLC acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at about $64,000. Finally, Wells Fargo & Company MN lifted its position in shares of Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after purchasing an additional 3,236 shares during the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.